Komzifti launched with early commerical traction - generating $2.1 million in net product revenue in the final weeks of 2025 - and achieved rapid market access (payers covering ~84% of private lives and ~90%% of insured lives pre-approval) aided by an NCCN Category 2A listing and fast payer decisions via KuraConnect. By MarketBeat | Original Article Is Kintara Therapeutics A Hidden Gem? Kura Oncology executives used the company's fourth-quarter and fiscal 2025 earnings call t

Agreement with EirGenix Inc. grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment of HER2-positive early breast cancer / metastatic breast cancer.